🚀 VC round data is live in beta, check it out!
Celyad Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Celyad Oncology and similar public comparables like Biofrontera, Anebulo Pharmaceuticals, Xintela, BioAtla and more.
Celyad Oncology Overview
About Celyad Oncology
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
Founded
2007
HQ
Employees
14
Website
Sectors
Financials (FY)
EV
$19M
Celyad Oncology Financials
Celyad Oncology reported last fiscal year revenue of — and negative EBITDA of ($45M).
In the same fiscal year, Celyad Oncology generated — in gross profit, ($45M) in EBITDA losses, and had net loss of ($47M).
Celyad Oncology P&L
In the most recent fiscal year, Celyad Oncology reported revenue of — and EBITDA of ($45M).
Celyad Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($45M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($47M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Celyad Oncology Stock Performance
Celyad Oncology has current market cap of $19M, and enterprise value of $19M.
Market Cap Evolution
Celyad Oncology's stock price is $0.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19M | $19M | -0.6% | XXX | XXX | XXX | $-1.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCelyad Oncology Valuation Multiples
Celyad Oncology trades at (0.4x) EV/EBITDA.
Celyad Oncology Financial Valuation Multiples
As of March 21, 2026, Celyad Oncology has market cap of $19M and EV of $19M.
Equity research analysts estimate Celyad Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celyad Oncology has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.8x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Celyad Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Celyad Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biofrontera | XXX | XXX | XXX | XXX | XXX | XXX |
| Anebulo Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Xintela | XXX | XXX | XXX | XXX | XXX | XXX |
| BioAtla | XXX | XXX | XXX | XXX | XXX | XXX |
| Citius Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celyad Oncology M&A Activity
Celyad Oncology acquired XXX companies to date.
Last acquisition by Celyad Oncology was on XXXXXXXX, XXXXX. Celyad Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Celyad Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCelyad Oncology Investment Activity
Celyad Oncology invested in XXX companies to date.
Celyad Oncology made its latest investment on XXXXXXXX, XXXXX. Celyad Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Celyad Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Celyad Oncology
| When was Celyad Oncology founded? | Celyad Oncology was founded in 2007. |
| Where is Celyad Oncology headquartered? | Celyad Oncology is headquartered in Belgium. |
| How many employees does Celyad Oncology have? | As of today, Celyad Oncology has over 14 employees. |
| Is Celyad Oncology publicly listed? | Yes, Celyad Oncology is a public company listed on Euronext Brussels. |
| What is the stock symbol of Celyad Oncology? | Celyad Oncology trades under CYAD ticker. |
| When did Celyad Oncology go public? | Celyad Oncology went public in 2013. |
| Who are competitors of Celyad Oncology? | Celyad Oncology main competitors are Biofrontera, Anebulo Pharmaceuticals, Xintela, BioAtla. |
| What is the current market cap of Celyad Oncology? | Celyad Oncology's current market cap is $19M. |
| Is Celyad Oncology profitable? | No, Celyad Oncology is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.